NCT03971461
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 14 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Results posted: Nov 17, 2026
- Secondary endpoints: 4 to 2
- Primary endpoint revised
- Notable Eligibility criteria expanded, about 40 words
- Secondary endpoints: details revised at 2 of 4 entries
- Minor Primary completion date changed from estimate of Jan 2026 to Apr 18, 2025v14
- Notable Primary completion date: Feb 2025 to Jan 2026
- Study completion date: Feb 2026 to Jan 2027
- Notable Primary completion date: May 2024 to Feb 2025
- Trial status: Recruiting to Active, Not Recruiting
- Study completion date: May 2025 to Feb 2026
- Site details revised at 2 of 2 sites
Show 8 earlier versionsHide 8 earlier versions
- Notable Primary completion date: May 2022 to May 2024
- Study completion date: May 2023 to May 2025
- Minor Site contacts updated at 1 of 2 sitesv9
- Minor Study sites: 1 to 2v8
- Minor Site contact updatedv7
- Notable Primary completion date: May 2020 to May 2022
- Eligibility criteria expanded, about 179 words
- Study completion date: May 2020 to May 2023
- Minor Site contact updatedv4
- Minor Site contact updatedv3
- Minor Study title shortened, about 5 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Progression Free Survival at 6 Months (PFS-6)
Timeframe: 6 Months
Secondary (2)
Overall Survival at 12 Months (OS-12)
Overall Survival (OS)
Arms and interventions
LutatheraExperimental
Drugs: Lutathera
Sites
2 sites in 1 country